My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

36.20 -1.12 (-3.00%)
Streaming Delayed Price Updated: 12:12 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
1 Safe-and-Steady Stock to Keep an Eye On and 2 Facing Headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
1 Stock Under $50 Worth Investigating and 2 We Ignore
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
3 Profitable Stocks We Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s... 
Via StockStory
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2%
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 29.4% year on year to $188 million. The company’s... 
Via StockStory
Collegium (COLL) Q2 Revenue Jumps 29%
Via The Motley Fool
Topics Intellectual Property
Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Record Q2 2025 Earnings and Raises Full-Year Guidance
Collegium Pharmaceutical (COLL) reports strong Q2 2025 earnings, beating estimates with $188M revenue (+29% YoY) and $1.68 EPS. Raised full-year guidance and new $150M buyback program signal growth... 
Via Chartmill
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
1 Cash-Producing Stock to Own for Decades and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
5 Hot Stocks With Summer Buybacks You Can Cash In On
The five stocks on this list issued aggressive buyback authorizations in June or July and have the power to follow through with their plans. 
Via MarketBeat
1 Safe-and-Steady Stock to Keep an Eye On and 2 to Be Wary Of
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Collegium Announces $150 Million Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your Radar
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company... 
Via StockStory
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
3 of Wall Street’s Favorite Stocks with Mounting Challenges
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
3 Small-Cap Stocks Facing Headwinds
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Collegium Announces $25 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company... 
Via StockStory
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.